Kornimate/medical-research-clean huggingface dataset:
treatment of unresectable colorectal metastases by radiofrequency ablation combined or not with resection, with or without neoadjuvant chemotherapy.

Conditions: Colorectal Cancer

Summary: the hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.


Eligibility criteria:
inclusion criteria: colorectal cancer hepatic metastases unresectable by classical surgery performance status \< 2 exclusion criteria: -

Keywords: radiofrequency ablation colorectal cancer liver metastases
cetirizine and famotidine for covid-19

Conditions: Covid19

Summary: this study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with covid-19. secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, icu admissions, and death.

covid-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov-2). patients with covid-19 may present with a myriad of symptoms ranging from fever and cough to more severe symptoms such as shortness of breath. cetirizine and famotidine are commonly administered medications that can be found over-the-counter. they are well tolerated and have low potential for drug-drug interaction. with it's anti-inflammatory properties via modulation of proinflammatory cytokines, cetirizine may be an effective symptomatic therapeutic for covid-19. with possible antiviral properties, famotidine may have a role in therapy as well. after a positive covid test has been confirmed, participants with be randomized to take cetirizine and famotidine or a placebo for 10 days and the study medication will be shipped to them. participants will record their symptoms for 30 days and any serious adverse events will be followed for up to 60 days.

Eligibility criteria:
inclusion criteria: * 18 years old and above * positive covid-19 test (antigen or pcr) * symptomatic from covid-19 * symptoms less than or equal to 7 days exclusion criteria: * already enrolled in another covid-19 drug study * chronically taking a h1-receptor antagonist or h2-receptor antagonist * have taken h1-receptor antagonist or h2-receptor antagonist less than 72 hours from expressed interest in the study. * history of an adverse reaction to h1 or h2-receptor antagonists * severe liver disease * severe renal disease * taking steroids * taking hydroxychloroquine and/or azithromycin * already participating in a covid-19 vaccine trial * already received a covid-19 vaccine * symptoms greater than 7 days * have had covid-19 more than once
efficacy and safety study of s-amlodipine gentisate compared to amlodipine besylate to treat mild-to-moderate hypertension

Conditions: Hypertension

Summary: the goal of this study is to compare the antihypertensive effect and tolerability of s-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate hypertension.


Eligibility criteria:
inclusion criteria: * patients are required to have a mean cuff sitting diastolic blood pressure of ≥90 and ≤109 mmhg after successful completion of the 2-week placebo run-in period exclusion criteria: * any serious disorder that could limit the ability of the patient to participate in the study * significant cardiovascular disease (angina, myocardial infarction, cerebrovascular disease, or significant arrhythmia in the preceding 6 months) * uncontrolled diabetes mellitus (serum glucose level ≥140 mg/dl) * insulin dependent diabetes mellitus (type i) * secondary hypertension

Keywords: hypertension
brinzolamide for the treatment of chronic central serous chorioretinopathy

Conditions: Central Serous Chorioretinopathy

Summary: examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

brinzolamide is a carbonic anhydrase inhibitor. previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. however, this treatment carries the risk of severe side effects. the goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.

Eligibility criteria:
inclusion criteria: * central serous chorioretinopathy (csc) affecting the fovea, non-resolving after 4 months of follow-up * optical coherence tomography (oct) shows foveal subretinal fluid * fluorescein angiography and indocyanine green confirm the diagnosis exclusion criteria: * any other ophthalmic condition that may lead to subretinal fluid * choroidal neovascularization * myopia \> -6d * previous treatment for csc in the past 6 months * known allergy to fluorescein or indocyanin green * known allergy for brinzolamide * pregnancy, breast feeding
gallstones and risk of inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the purpose of this study was to evaluate the association between gallstone disease and the risk of inflammatory bowel disease.

crohn's disease and ulcerative colitis , collectively known as inflammatory bowel diseases , have increased substantially over the past few decades affecting nearly 6.8 million individuals worldwide. the etiology of ibd remains obscure, possibly involving a complex interaction between the genetic, environmental or microbial factors and the immune responses. gallstone disease is one of the most common and costly gastroenterological disorders, with a prevalence of 10-20% in europe and america. considering that gallstones and ibd also share specific risk factors, such as obesity, inappropriate diet and metabolic hormone levels, and have the pathophysiologic linkage, such as changes in gut microbiota composition and bile acid profile, the investigators propose that the occurrence of gallstones may predict the subsequence risk of ibd. however, investigations concerning the association is lacking.

Eligibility criteria:
inclusion criteria: * age between 18 and 90 years old * ibd established by standard criteria, either crohn's disease or ulcerative colitis exclusion criteria: * pregnant or nursing woman; * prior abdominal surgery related to ibd, such as subtotal or total colectomy; * hiv infection or any congenital immunodeficiency at the time of inclusion; * post organ transplant patients; * patients suffering from cancer currently or in the past; * patients suffering from significant cardiovascular disease; * patients suffering from significant respiratory diseases; * patients suffering from any other chronic severe diseases.

Keywords: gallstone crohn's disease ulcerative colitis
clinical study of ultrasonic artificial intelligence and fine needle aspiration in qualitative diagnosis of thyroid nodules

Conditions: Thyroid Nodule

Summary: to study the value of thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules, so as to provide evidence-based medical evidence for the diagnosis of benign and malignant thyroid nodules by artificial intelligence.


Eligibility criteria:
inclusion criteria: * (1) age 18-75 years old, regardless of gender; (2) the nodules were observed with complete transverse and longitudinal standard sections; (3) the nodules were observed and underwent thyroid fine needle aspiration, including cytology and braf gene mutation detection; (4) patients voluntarily entered the study after informed consent. exclusion criteria: * (1) if the observed nodule is less than 2mm or more than 50mm, the artificial intelligence system cannot recognize it; (2) uncontrolled subacute thyroiditis and hyperthyroidism; (3) previous thyroid surgery or radiofrequency ablation of thyroid nodules; (4) history of neck trauma.
intraoperative versus postoperative thymoglobulin in lung transplantation

Conditions: Lung Transplant

Summary: the purpose of this study is to take a population of lung transplant recipients who meet ucla criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus postoperatively makes a difference with how patients do during and after lung transplantation.

the purpose of this study is to take a population of lung transplant recipients who meet ucla criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus postoperatively makes a difference with how patients do during and after lung transplantation. in addition, these cohorts will be compared to patients who do not qualify for thymoglobulin and receive either an alternative agent or no agent. the primary endpoint is primary graft dysfunction. we will also evaluate several other early and late end points such as ventilator days, icu/hospital days, acute/chronic rejection, infection, ct chest abnormalities, and survival. we will also collect donor lung tissue and lavage fluid for measurement of various proteins and receptor expression at two time points: (1) prior to implementation and dosing of induction chemotherapy and (2) after transplantation (following a course of induction chemotherapy). this will allow us to possibly make a connection between the profiles of the various proteins and receptors and the clinical outcomes, depending on weather the patient has received induction chemotherapy, starting intraoperatively or postoperatively.

Eligibility criteria:
inclusion criteria: * on a voluntary basis, all patients eligible for bilateral lung transplantation between the ages of 18-65 years (inclusive) exclusion criteria: * have any known allergy to horse or rabbit antithymocyte polyclonal agents * have a preoperative platelet count less then 100,000/mm3 * are recipients of multiple organ transplants (either simultaneous or sequential) * are recipients of a single lung transplantation * have a contraindication to rabbit antithymocyte globulin based on judgement of the investigators (i.e. bleeding diathesis or overwhelming risk of intense immunosuppression) including the following patients: greater than 65 years of age, prior diagnosis of malignancy (with the exception skin malignancies), underlying suppurative lung disease (i.e. bronchiectasis, cystic fibrosis, etc.).

Keywords: atg rabbit thymoglobulin reperfusion lung injury primary graft dysfunction lung transplantation
the effects of mechnikov probiotics on symptom and surgical outcome

Conditions: Sigmoid Colon Cancer

Summary: the purpose of this clinical trial study was to evaluate the prevalence of colon cancer among the symptom (s) of anterior resection syndrome that may occur after surgery in patients for efficacy and safety in metchnik probiotic ingestion.

the purpose of the clinical trial is to evaluate the efficacy and safety of the syndrome that may occur after colon cancer surgery, to evaluate the efficacy and safety of the improvement effect of the defecatory activity on the improvement of the medienkov probiotics biotics on the patients who have the deficit function and planned to surgery.

Eligibility criteria:
inclusion criteria: 1. adult male or female aged 20 to over 75 years old 2. as histologically and radiologically diagnosed s colon cancer, those who is scheduled for anterior resection 3. those who have been agreed to participate in this trial (through informed consent) before initiation of clinical trial. exclusion criteria: 1. those who have metastatic colorectal cancer screening 2. those who have urinary incontinence or fecal incontinence 3. those who received preoperative chemotherapy or radiotherapy 4. those who have a history of severe cerebral vascular disease (cerebral infarction, cerebral hemorrhage, etc.), severe cardiac disease (unstable angina pectoris, myocardial infarction, arrhythmia requiring heart failure heart failure therapy) 5. those who have neurologist or psychologically important psychiatric history or current disease 6. those who have alcohol addiction, substance abuse 7. those who have immune system, infectious infectious disease, gastrointestinal tract disease patients (inflammatory bowel disease) 8. those who have uncontrolled hypertension, diabetes patients 9. those who have creatinine with more than twice from normal upper limit in site 10. those who have ast(got) or alt(gpt) with more than three times from normal upper limit in site 11. those who have probiotics, antibiotics, continually within the last one week 12. those who is pregnant women, breastfeeding women and have pregnancy plans or do not agree to appropriate contraception methods choice 13. those who have been participated within three months or have plans to participate in another clinical trial after the start of this clinical trial 14. under the investigator's judgment, those who is not qualified to participate this clinical trial
postural assessment, therapeutic exercise and orthotic devices in the prevention of haemophilic arthropathy

Conditions: Haemophilic Arthropathy; Orthosis; Foot Malalignment

Summary: haemophilic arthropathy (ha) is the most frequent complication of haemophilia and is often associated with a severe deterioration in quality of life. it is caused by repeated joint bleeding resulting in chronic proliferative synovitis and progressive destruction of articular cartilage. the most frequently affected joints are the knees, ankles and elbows. the aim of this study is to verify the use of lower limb orthoses in combination with postural rehabilitation, assessing the incidence of spontaneous haemarthroses and haematomas as the primary endpoint and pain and qol as secondary endpoints. we conducted a prospective observational, randomised and controlled study on outpatients attending the uoc of recovery and functional rehabilitation of the aoup paolo giaccone of palermo for haemophilic arthropathy sent by the uo of haematology of the same hospital. the study period was between january 2017 and march 2023. the patients recruited were randomly divided into two groups by means of a computer-generated random number system: group a, consisting of patients who were prescribed orthoses and a 20-session rehabilitation programme; group b, consisting of patients who were only prescribed orthoses for the lower limbs. the rehabilitation programme was based on the back school method. all patients were assessed at baseline (t0), at 3 months (t1) and after 6 months (t2). two arthropathic-specific scales were used to assess outcomes, namely the hemophilia joint health score (hjhs), which reflects joint function and status, and the functional independence score in hemophilia (fish), which relates to the patient\&#39;s quality of life. we also used the numerical rating scale (nrs) for joint pain. finally, postural assessment was performed in static posture, observing the patient\&#39;s alignment in different planes and using the apecs (ai posture evaluation and correction system ®) mobile app. during the re-evaluations, any new haemarthroses and haematomas were also assessed.


Eligibility criteria:
inclusion criteria: * diagnosis of severe haemophilia a or b; * age ≥ 6 years and ≤ 50 years; * presence of hindfoot and/or arch misalignment; * prophylaxis with factor deficient (viii or ix). exclusion criteria: * patients with prosthetic implants/synthetic means * uncooperative patients

Keywords: haemophilic arthropathy orthosis postural assestment foot malalignment therapeutic exercise haemarthroses haematomas hjhs fish
chemotherapy, radiation therapy, and surgery in treating patients with locally advanced cancer of the vulva

Conditions: Stage III Vulvar Cancer; Stage IVB Vulvar Cancer; Vulvar Squamous Cell Carcinoma

Summary: this phase ii trial is studying how well giving radiation therapy together with cisplatin followed by surgery works in treating patients with locally advanced cancer of the vulva. drugs used in chemotherapy such as cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. giving chemotherapy with radiation therapy before surgery may shrink the tumor so it can be removed during surgery.

objectives: i. determine the efficacy of radiotherapy and cisplatin, in terms of achieving a complete clinical and pathological response, in patients with locally advanced squamous cell carcinoma of the vulva that is not amenable to standard radical vulvectomy. ii. determine the toxicity of this regimen followed by surgery in these patients. outline: this is a multicenter study. patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin iv over 30 minutes on day 1. treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity. six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * diagnosis of locally advanced squamous cell carcinoma of the vulva * t3 or t4 (n0-3, m0) * not amenable to surgical resection by standard radical vulvectomy * previously untreated disease * no recurrent disease * no vulvar melanoma or sarcoma * performance status - gog 0-3 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin no greater than 1.5 times normal * alkaline phosphatase no greater than 3 times normal * sgot no greater than 3 times normal * creatinine no greater than 2.0 mg/dl * no gastrointestinal bleeding * no severe gastrointestinal symptoms * capable of tolerating a radical course of chemoradiotherapy * no septicemia * no severe infection * no other invasive malignancy within the past 5 years except nonmelanoma skin cancer * no circumstance that would preclude study completion or follow-up * no prior cytotoxic chemotherapy * no prior pelvic radiotherapy * no concurrent boost brachytherapy * no prior anticancer therapy that would contraindicate study therapy
oral oxytocin modulation of responses to emotional stimuli

Conditions: Healthy

Summary: the main aim of the study is to investigate whether orally administered oxytocin (24iu) can modulate neural and behavioral responses to positive and negative valence stimuli during basal (emotional scenes) and higher order (facial stimuli) emotional processing.

a number of previous studies have reported both neural and social cognition effects of intranasally administered oxytocin, although it is unclear whether functional effects are mediated by the peptide directly entering the brain or indirectly via raising peripheral concentrations. the investigators hypothesize that one method of producing a similar pattern of increased peripheral oxytocin concentrations but without the possibility of direct entry into the brain would be to administer the peptide lingually. in the current double-blind, between-subject, placebo controlled study 80 healthy male subjects will be recruited and receive either oxytocin (24iu) or placebo control administered orally (lingual). 45 minutes after treatment subjects will be required to complete both face emotion and emotional scene processing tasks during fmri scanning. after the tasks, subjects will be required to rate their valence, intensity and arousal response to the same emotional face and scene stimuli which were presented during mri acquisition. blood samples will be taken before and 30 min after the oral treatment interventions to assess oxytocin blood concentrations. all subjects will be asked to complete a range of questionnaires before treatment to control for possible pre-treatment confounders in terms of personality traits and mood: beck depression inventory ii (bdi), autism spectrum quotient (asq), liebowitz social anxiety scale (lsas), state-trait anxiety inventory (stai), childhood trauma questionnaire (ctq), the second version of social responsiveness scale(srs-2), and interpersonal reactivity index (iri).

Eligibility criteria:
inclusion criteria: * healthy subjects without any past or present psychiatric or neurological disorders exclusion criteria: * history of brain injury * head trauma * substance abuse * medication * fmri contraindications (e.g. metal implants)

Keywords: oral oxytocin emotional processing anxiety reward
hfnc versus conventional nasal cannula in oxygen performance in patients receiving colonoscopy under iv sedation

Conditions: Desaturation of Blood

Summary: the purpose of this study is to investigate if high flow nasal cannula (hfnc), as compared to conventional nasal cannula, improves oxygenation and prevents desaturation events in obese patients undergoing colonoscopy.

intravenous sedation during colonoscopy has become the standard practice in united states given its higher patient satisfaction and procedural quality. the most common used short acting sedative agent is propofol. although possessing safe and rapidly reversed pharmacokinetic properties, propofol intravenous infusion can lead to respiratory depression and hypoxemia. in one prospective study, hypoxemia events, defined by oxygen saturation less than 90 percent was found in 20 percent of patients receiving colonoscopy using propofol sedation. the mechanism of hypoxemia is mainly hypoventilation, airway collapse, and carbon dioxide (co2) retention. when it comes to gastrointestinal procedures, using oxygen devices for augmenting ventilation is usually avoided, ex: positive pressure ventilation, since it can lead to bowel distention and affect quality of procedures. therefore most hospitals in united states still use nasal cannula of oxygen therapy during gastrointestinal procedures, and there is lack of available options of oxygen therapy which can improve hypoventilation and prevent hypoxemia. high flow nasal cannula (hfnc) is a new generation of oxygen therapy. it provides constant high flow oxygen delivery with heated and humidified air. moreover, it has been studied that high velocity of airflow can create the effect of "positive end expiratory pressure" thus assist ventilation and work of breathing. compared to conventional nasal cannula and face mask, hfnc has demonstrated superior performance in oxygenation, work of breathing and patient comfort in many studies. since its invention, hfnc has been studied in post-cardiac surgery, post-extubation, bronchoscopy and dental procedures and all of them show equal to better oxygen performance in comparison of nasal cannula. while capnographic monitoring has been studied to prevent hypoxemia during sedation, no studies have been done to evaluate the clinical utility of new generation oxygen therapy. obesity is associated with increased frequency of sedation related complications especially hypoxemia during propofol mediated sedation for advanced endoscopic procedures. the investigators hypothesized that hfnc may improve oxygen performance compared to conventional nasal cannula for obese patients receiving colonoscopy under intravenous sedation.

Eligibility criteria:
inclusion criteria: * bmi ≥ 30. * age ≥ 18 years. * asa classification ii and iii. * scheduled for colonoscopy. * able to provide written informed consent. exclusion criteria: * allergic to propofol and any of its contents. * baseline spo2 less than 93%. * patients who require intubation for airway protection based on anesthesiologist discretion.

Keywords: high flow nasal cannula colonoscopy obesity